View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
November 9, 2020

Long HCC pipeline marks change for a previously stagnant market

By GlobalData Healthcare

Despite the high unmet needs within hepatocellular carcinoma (HCC), the market was stagnant from 2007 until 2018, when the FDA approved Eisai’s Lenvima (lenvatinib) in first-line advanced HCC. Currently, the HCC treatment landscape is continuing to change rapidly. Notably, the combination of Genentech’s Avastin (bevacizumab) and Tecentriq (atezolizumab) for the treatment of first-line advanced HCC, which was approved in May 2020, was more effective than the previous standard of care, Bayer’s Nexavar (sorafenib). Patients with advanced HCC are not suitable for curative treatments due to the extent of the disease and reduced liver function. Therefore, non-curative treatments such as systemic therapy aim to escalate survival and improve the patient’s quality of life.

Numerous ongoing Phase III clinical trials are aiming to expand HCC treatment options even further. Current mechanisms of action (MOAs) under investigation in Phase III trials to treat patients with advanced HCC include multikinase inhibitors, angiogenesis inhibitors, and immuno-oncology agents (PD-1/PD-L1 and CLTA-4 inhibitors). Phase I and II pipeline also contains novel MOAs, such as immunomodulators, protein/peptide-based cancer vaccines, a stemness inhibitor, adoptive cellular therapy, and chemotherapy. Key opinion leaders interviewed by GlobalData noted that adoptive cellular therapy is an emerging novel target that may change HCC treatment practice.

The HCC systemic therapy landscape has evolved not only in the advanced stage but also in the earlier stages of HCC. Currently, patients with early stage HCC receive surgical resection, transplantation, and ablation. While adjuvant therapy has improved outcomes over surgery alone in other cancer types, there are no such therapies to decrease the incidence of recurrence in HCC. Similarly, patients with intermediate HCC with more widespread liver-confined disease have limited treatment options that consist of locoregional therapies, such as transarterial embolization (TACE). Systemic therapies are being investigated in combination with surgery as adjuvant therapy for early stage patients and as combinations with TACE for intermediate-stage patients. Label expansions into early and intermediate HCC would be an effective strategy for companies to gain market share in this space.

Figure 1 presents the crowded Phase I, II, and III agents in HCC, segmented by MOA.

Figure 1: Overview of the HCC Development Pipeline.

Credit: GlobalData.

The needs in the HCC space are likely to be met, as many new therapies entering the market have different MOAs and are aiming to meet needs in different treatment settings. The variety of pipeline products for the early, intermediate, and advanced HCC settings brings hope for improvements to the cure rate for early stage HCC and survival for all stages.

Cell & Gene Therapy Coverage on Pharmaceutical Technology supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology